Profile: julio riddle |
| ABC@home member since | 16 Aug 2009 |
| Country | United States |
| Total credit | 0.00 |
| Recent average credit | 0.00 |
| Team | None |
| Computers | View |
| Contact | Send private message |
| Your personal background. | |
| BUY SLEEPING PILLS - FREE RX, USA PHARMACY | |
| Your opinions about ABC@home | |
Patients should tell their healthcare provider right away if they have any conditions, including the following. "These data suggest that long-term treatment with BARACLUDE has the potential to stop liver damage and may even improve insomnia medicine liver fibrosis caused by chronic hepatitis B infection," said Professor Yun-Fan Liaw, lead investigator for the Long-term Histology Cohort (subset of ETV-901), from Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. Visit Bristol-Myers Squibb at. BARACLUDE(R) has been approved in more than 86 countries and regions around the world. BARACLUDE does not cure insomnia medicine HBV or stop the spread of HBV to others. The histology data were presented today at the 59th Annual Meeting of the American Association for the Study of Liver Diseases. The long-term histology cohort included 57 nucleoside-naive patients who received a minimum of 3 years of cumulative therapy with BARACLUDE from the start of studies ETV-022 or -027(1,2) (BARACLUDE 0.5 mg) to the time of their last observed biopsy in ETV-901 (BARACLUDE 1 mg), sleep medications and had adequate baseline and long-term liver biopsies. Of these 64 patients, 100 percent (37/37) of treatment-naive patients and 89 percent (23/26) of lamivudine-refractory patients experienced improvement in liver histology (measured by a greater than or equal to a two-point decrease in Knodell necroinflammatory score), and 47 percent (17/36) of treatment-naive and 32 percent (8/25) of lamivudine-refractory sleep meds patients experienced an improvement in liver fibrosis (greater than or equal to a one-point decrease in Knodell fibrosis score). Histology results were also presented from the open-label rollover study ETV-060, which evaluated Japanese patients with chronic hepatitis B. -- Feeling very weak or tired, unusual muscle pain, trouble breathing, stomach pain with nausea and vomiting, feeling cold (especially in the arms and legs), feeling dizzy or lightheaded, or a fast or irregular heartbeat may be signs of a serious condition rozerem called lactic acidosis (buildup of an acid in the blood). -- Grade 3-4 adverse event(s) were reported in 20% of patients, and serious adverse event(s) were reported in 25%. Control of viral replication is an important goal of chronic hepatitis B treatment. -- At week 148, 95% (35/37) of treatment-naive patients and 56% (15/27) of lamivudine-refractory patients had HBV DNA less than 400 copies/mL. These patients were treated with BARACLUDE for a median of six years. New long-term histology results were presented from a cohort of 57 nucleoside-naive patients sleep medications from rollover study ETV-901. Please see accompanying Full Prescribing Information, including boxed WARNINGS, or visit or /. The most com adverse events were upper respiratory tract infection (23%); headache (16%); nasopharyngitis, an inflammation of the nose and throat (16%); ALT increase, an increase in the production of the liver enzyme ALT, which may indicate inflammation of the liver or liver damage (14%); abdominal pain (13%); influenza (13%); back pain (12%); pyrexia-fever (12%); arthralgia-joint pain (10%); cough (10%); hypertension (10%); insomnia (10%); and pharyngolaryngeal pain - throat pain (10%). rozerem -- Yellowing (jaundice) of the skin or the white part of the eyes, darkening of the urine, lightening in the color of bowel movements (stools), not feeling like eating food for several days or longer, feeling sick to the stomach (nausea), or having lower stomach pain, may be signs of serious liver problems called hepatotoxicity. Of the 57 patients, 96 percent (55/57) experienced improvement in liver histology (improvement in how the liver tissue looks under a microscope). Patients should not stop taking BARACLUDE without talking to their healthcare provider. The safety and effectiveness of BARACLUDE in liver transplant recipients are unknown. For patients ramelteon taking BARACLUDE to treat chronic hepatitis B and not taking medicines for HIV at the same time, some HIV treatments that they take in the future may be less likely to work. -- 100% of patients achieved undetectable viral load (HBV DNA less than 300 copies/mL by PCR). Healthcare providers may want to do tests to see if a lower dose is needed or if BARACLUDE should be taken less often than once a ramelteon day. Indication and Important Safety Information About BARACLUDE 0.5 mg and 1 mg Tablets BARACLUDE is a prescription medicine used for chronic infection with hepatitis B virus (HBV) in adults where the virus is multiplying and damaging the liver. A pregnant woman and her healthcare provider will need to decide if BARACLUDE sleep meds is right for her. Improvement in liver histology was defined as greater than or equal to a two-point decrease in Knodell necroinflammatory score and no worsening of Knodell fibrosis score. This list of side effects is not complete at this time because BARACLUDE is still under study. Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life. insomnia medication -- Pregnant or planning to become pregnant. ETV-901 provided long-term treatment with BARACLUDE 1 mg for patients who completed phase 2-3 studies. It is not known if BARACLUDE helps to prevent a pregnant mother from passing HBV to her baby. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. This has happened in some patients who have taken medicines like BARACLUDE. sleeping medications Additionally, 88 percent of patients (50/57) experienced a reduction in liver fibrosis, defined as improvement in Ishak fibrosis score (greater than or equal to a one-point decrease). The current analysis evaluated the long-term histologic results for patients who had liver biopsies after receiving at least three years of continuous treatment with BARACLUDE (37 patients from ETV-053 and 27 patients from ETV-052). Endnotes One patient had a baseline biopsy not evaluable for necroinflammation One patient had a baseline biopsy sleeping pills not evaluable for fibrosis Two patients had baseline biopsies not evaluable for fibrosis References 1. Patients should report any new or continuing symptom to their healthcare provider. About Chronic Hepatitis B Chronic hepatitis B is a serious global health issue. These patients must be carefully monitored before and during treatment with BARACLUDE, and they should discuss treatment with their doctor. Patients should discuss with their healthcare provider all prescription and non-prescription medicines, vitamins, sleep medicine herbal supplements, and other health preparations they are taking or plan to take. -- Patients who have or get HIV infection (the virus that can cause AIDS). At the time of the ETV-901 long-term biopsy, 100 percent of subjects with evaluable liver biopsies (57/57) had undetectable viral load (HBV DNA less than 300 copies/mL by polymerase chain reaction (PCR)). Lactic acidosis is a medical emergency and must be treated in the hospital. T/mediacentre/factsheets/fs204/en/. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, You-Chen C, et al. In the ETV-060 rollover study, patients continued treatment with BARACLUDE at 0.5 mg (treatment-naive patients) or 1 mg (lamivudine-refractory patients). A woman should not breastfeed if she is taking BARACLUDE. This has happened in some patients taking medicines like BARACLUDE(R). Histologic improvement (greater than or equal to a two-point decrease in Knodell necroinflammatory score) and improvement in Knodell fibrosis score (greater than or equal to a one-point decrease) were evaluated for patients with biopsies at baseline, Week 48 and Week 148. The most com side effects of BARACLUDE(R) in clinical studies were headache, tiredness, dizziness, and nausea. About the ETV-060 Analysis ETV-060 was an open-label rollover study of Japanese chronic hepatitis B patients, including 66 treatment-naive patients who completed 52 weeks of treatment with BARACLUDE(R) 0.1 mg or 0.5 mg in study ETV-053, and 82 lamivudine-refractory patients who completed 52 weeks of treatment with BARACLUDE 0.5 mg or 1 mg in study ETV-052. "The ability to provide effective long-term treatment with a potent antiviral with minimal resistance represents a positive step forward." About the ETV-901 Analysis ETV-901 is a long-term rollover study for patients who previously completed phase 2-3 entecavir studies. Results of patients in ETV-901 who agreed to undergo long-term liver biopsies (median of 6 years of treatment) -- 96% of patients had improvement in liver histology at long-term liver biopsy - an increase from 73% at week 48. -- Of the 43 patients with a baseline fibrosis score of greater than or equal to 2, 58% had a 2-point or more decrease in Ishak fibrosis score. Patients should not take BARACLUDE if they are allergic to any of its ingredients. Lai CL, Shouval D, Lok A, Chang TT, Cheinquer H, Goodman Z, et al. World Health Organization Web site. Asian Liver Center Web site. Bristol-Myers Squibb Company (NYSE:BMY) today announced data from two separate cohort evaluations, in which long-term treatment with BARACLUDE(R) (entecavir) was associated with improved liver histology, including improvement in fibrosis, in chronic hepatitis B patients. BARACLUDE(R) (entecavir) is a registered trademark of Bristol-Myers Squibb Company. FAQ About Hepatitis B. The co-primary long term histology endpoints were the proportion of patients with histologic improvement (defined as greater than or equal to a two-point decrease in Knodell necroinflammatory score and no worsening of Knodell fibrosis score) and the proportion of patients with improvement in Ishak fibrosis score (greater than or equal to a one-point decrease), both compared to baseline. Please see the following Important Safety Information for BARACLUDE, including boxed WARNINGS in bold. -- Worsening of HBV infection if patients stop taking BARACLUDE. BARACLUDE will not help HIV infection. Fibrosis occurs when excessive fibrous connective tissue builds up in the liver in response to chronic inflammation, which can be caused by chronic hepatitis B infection. Hepatitis B symptoms may get worse or become very serious if they stop taking BARACLUDE. Patients follo in this cohort received BARACLUDE for a median of six years across the studies (ETV-022, -027 and -901) and had evaluable baseline and long-term liver biopsies. -- Safety results for this cohort analysis were not reported at this conference. BARACLUDE may interact with medicines that leave the body through the kidneys. BARACLUDE has not been studied in children and is not recommended for anyone less than 16 years old. Fact sheet N(degree)204. This cohort included 37 treatment-naive patients and 27 patients resistant to treatment with lamivudine from two Phase 2 studies (ETV-053, ETV-052) who had liver biopsies after receiving at least three years of treatment with BARACLUDE(R). It is not known if BARACLUDE is safe to use during pregnancy. Because BARACLUDE is removed from the body through the kidneys, a lower dose or a different dose schedule may be needed. Worldwide, more than two billion people (one out of every three people) have been infected with the hepatitis B virus and approximately 350 million people are chronically infected(3,4). BARACLUDE should be taken exactly as prescribed and on an empty stomach (at least two hours after a meal and at least two hours before the next meal). Results of patients in ETV-060 who agreed to undergo long-term liver biopsies (at least 3 years of treatment) -- Among both treatment-naive and lamivudine-refractory CHB patients, liver histology improved after three years of continuous BARACLUDE(R) treatment. This may occur with liver enlargement (hepatomegaly) and fat in the liver (steatosis). About BARACLUDE Discovered at Bristol-Myers Squibb, BARACLUDE is a nucleoside analogue indicated for use in adults with chronic hepatitis B infection with compensated liver disease, evidence of active viral replication, and either evidence of persistent elevations of the blood levels of aminotransferases - a marker for liver disease - or active liver disease as determined by biopsy. -- The proportion of patients with improvement in Ishak fibrosis score increased from 32% at 48 weeks to 88% at long-term liver biopsy. At week 148, 100% (37/37) of treatment-naive patients and 89% (23/26) of lamivudine-refractory patients experienced improvement in Knodell necroinflammatory score, and 47% (17/36) of treatment-naive and 32% (8/25) of lamivudine-refractory patients experienced an improvement in liver fibrosis as measured by the Knodell fibrosis score. An estimated 1.25 million Americans are chronically infected with hepatitis B, and over half are of Asian descent(4). Healthcare providers will need to follow their patients and do blood tests to check the liver if BARACLUDE is stopped. Patients are advised to get an HIV test before starting to take BARACLUDE and anytime after that when there is a chance they were exposed to HIV. A service of YellowBrix, Inc.. Patients taking BARACLUDE should tell their healthcare provider right away if they have any side effects or conditions, including the following. | |
| Your feedback on this profile | |
| Recommend this profile for User of the Day: | I like this profile |
| Alert administrators to an offensive profile: | I don't like this profile |